A RNA Interference Screen Identifies RIP3 as an Essential Inducer of TNF-Induced Programmed Necrosis

  • YoungSik Cho
  • Sreerupa Challa
  • Francis Ka-Ming Chan
Conference paper

DOI: 10.1007/978-1-4419-6612-4_62

Volume 691 of the book series Advances in Experimental Medicine and Biology (AEMB)
Cite this paper as:
Cho Y., Challa S., Chan F.KM. (2011) A RNA Interference Screen Identifies RIP3 as an Essential Inducer of TNF-Induced Programmed Necrosis. In: Wallach D., Kovalenko A., Feldmann M. (eds) Advances in TNF Family Research. Advances in Experimental Medicine and Biology, vol 691. Springer, New York, NY

Abstract

Recent evidence indicates that TNF-like death cytokines can induce apoptotic and non-apoptotic forms of cell death. We have coined the term “programmed necrosis” to describe caspase-independent cell death induced by TNF-like cytokines. Besides an obligate requirement for the protein serine/threonine kinase RIP1 and the production of reactive oxygen species (ROS), relatively little is known about the molecular mechanisms that control TNF-induced programmed necrosis. In order to further illuminate the molecular pathway that governs programmed necrosis, we performed a targeted RNA interference (RNAi) screen. Our screen identified RIP3, a RIP1 family member, as a specific mediator for programmed necrosis, but not apoptosis. Biochemical analyses show that assembly of the pro-necrotic RIP1–RIP3 complex critically regulates induction of programmed necrosis. The physiological relevance of RIP3-dependent programmed necrosis is demonstrated by the failure of RIP3-deficient mice to control vaccinia virus infections.

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • YoungSik Cho
    • 1
    • 2
    • 3
  • Sreerupa Challa
    • 1
  • Francis Ka-Ming Chan
    • 1
  1. 1.Department of PathologyUniversity of Massachusetts Medical SchoolWorcesterUSA
  2. 2.Immunology and Virology ProgramUniversity of Massachusetts Medical SchoolWorcesterUSA
  3. 3.Center for Metabolic Syndrome Therapeutics, Bio-Organic Science DivisionKorea Research Institute of Chemical TechnologyDaejeonKorea